{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:44:13Z","timestamp":1779223453346,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe a case report of antiretroviral regimen selection, with considerations for drug-supplement interactions, for a patient living with HIV with complicated nutrition needs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>A 56-year-old white female with a history of sleeve gastrectomy was initiated on coformulated bictegravir\/emtricitabine\/tenofovir alafenamide for treatment of HIV infection. Her baseline HIV viral load was 139,790 RNA copies\/mL, and the baseline CD4 cell count was 544 cells\/mm3. The patient additionally had a nutritional supplement regimen of twice-daily calcium and twice-daily multivitamins with minerals following sleeve gastrectomy. Due to binding interactions between polyvalent cations and bictegravir and the potential impact on antiretroviral efficacy, construction of a daily medication schedule to avoid interactions between the antiretroviral regimen and the supplements while promoting optimal dosing of each supplement was necessary; however there is currently no guidance on twice-daily cation dosing with coadministered bictegravir and limited guidance on multivitamin coadministration in this context. A review of the available literature on bictegravir interactions and pharmacokinetic parameters was performed. A dose separation strategy was utilized to design a regimen that maximized separation of doses of supplements from doses of bictegravir\/emtricitabine\/tenofovir alafenamide while minimizing interaction potential. At follow-up 8 weeks after regimen initiation, the HIV viral load was undetectable (&amp;lt;40 copies\/mL) and the CD4 cell count had increased to 821 cells\/mm3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Integrase strand transferase inhibitor interactions with polyvalent cations in nutritional supplements can be avoided or mitigated with attention to timing of each dose and optimizing separation strategies. This case report shows the potential for alleviating such interactions through optimal dose scheduling.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxac324","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:43:51Z","timestamp":1666986231000},"page":"196-199","source":"Crossref","is-referenced-by-count":2,"title":["Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature"],"prefix":"10.1093","volume":"80","author":[{"given":"Lindsey","family":"Buscemi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Virginia Health System , Charlottesville, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Mossholder","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Pharmacy , Richmond, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"2023021517192513300_","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services."},{"issue":"1","key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.11.004","article-title":"Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy","volume":"85","author":"McColl","year":"2010","journal-title":"Antiviral Res"},{"key":"2023021517192513300_","author":"Liverpool Drug Interactions Group, University of Liverpool."},{"issue":"5","key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5688\/aj7005100","article-title":"The pharmacology of HIV drug resistance","volume":"70","author":"Zdanowicz","year":"2006","journal-title":"Am J Pharm Educ"},{"key":"2023021517192513300_","article-title":"Prescribing information. Gilead Sciences;","author":"Biktarvy.","year":"2021"},{"issue":"1","key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","article-title":"Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults","volume":"75","author":"Gallant","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023021517192513300_","first-page":"203","article-title":"Profile of bictegravir\/emtricitabine\/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date","volume":"10","author":"Hill","year":"2018","journal-title":"HIV AIDS (Auckl)"},{"issue":"3","key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40121-020-00307-4","article-title":"HIV-1 virologic rebound due to coadministration of divalent cations and bictegravir","volume":"9","author":"Rock","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2023021517192513300_","author":"Liverpool HIV Pharmacology Group, University of Liverpool."},{"issue":"1","key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s001980050111","article-title":"Absorption of calcium as the carbonate and citrate salts, with some observations on method","volume":"9","author":"Heaney","year":"1999","journal-title":"Osteoporos Int"},{"key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/jcpt.12755","article-title":"Antiretroviral considerations in HIV-infected patients undergoing bariatric surgery","volume":"43","author":"Cimino","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40262-022-01120-7","article-title":"Implications of bariatric surgery on the pharmacokinetics of antiretrovirals in people living with HIV","volume":"61","author":"Zino","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2023021517192513300_","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1093\/jac\/dkab319","article-title":"Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV","volume":"76","author":"Tempestilli","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac324\/46852677\/zxac324.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/4\/196\/49200400\/zxac324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/4\/196\/49200400\/zxac324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T13:31:59Z","timestamp":1678455119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/4\/196\/6779624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,28]]},"published-print":{"date-parts":[[2023,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac324","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,15]]},"published":{"date-parts":[[2022,10,28]]}}}